Trading / Browse Companies / Inozyme Pharma Stock

Inozyme Pharma Stock

inozyme.comHealthcareFounded: 2016Funding to Date: $115.85MM

Inozyme Pharma is a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases.

Buy or sell Inozyme Pharma stockLearn more about a potential Inozyme Pharma IPO
Register for Details

For more details on financing and valuation for Inozyme Pharma, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Inozyme Pharma.

Register Today

Team

Management Team

Henric Bjarke
Chief Operating Officer & Senior Vice President
Stephen Basso
Vice President of Finance
Joseph Schlessinger Ph.D
Co-Founder & Chairman
Steven Jungles
Chief Technical Operations Officer & Senior Vice President
David Thompson
Senior Vice President & Chief Scientific Officer
Eric Yuen MD
Chief Medical Officer & Senior Vice President
Axel Bolte
Co-Founder, Chief Executive Officer, President & Board Member
Ruhi Ahmed Ph.D
Vice President of Regulatory and Government Affairs
Demetrios Braddock Ph.D
Scientific Founder, Chairperson of Scientific Advisory Board and Board Observer

Board Members

Axel Bolte
Joseph Schlessinger Ph.D
Rob Hopfner
Demetrios Braddock Ph.D
Martin Edwards MD
Novo Holdings
Ruchita Sinha
Sanofi-Genzyme Bioventures
Edward Mathers
New Enterprise Associates
Reinaldo Diaz
Longitude Capital
Sarah Bhagat Ph.D
Sofinnova Investments

Other companies like Inozyme Pharma in the Healthcare sector

Altos Labs
Sector
Healthcare
Last Round Est. Valuation
$3.6B
Neuralink
Sector
Healthcare
Last Round Est. Valuation
$2.15B
NowRx
Sector
Healthcare
Last Round Est. Valuation
$334.19MM
Nutrafol
Sector
Healthcare
Last Round Est. Valuation
$150MM
Biosplice Therapeutics
Sector
Healthcare
 
 
Cytonics
Sector
Healthcare
 
 
Cerebral
Sector
Healthcare
Last Round Est. Valuation
$4.8B
Mammoth Biosciences
Sector
Healthcare
Last Round Est. Valuation
$1.08B
Levels
Sector
Healthcare
Last Round Est. Valuation
$296.3MM

News

Business Wire 11/14/2019
Inozyme Pharma Expands Medical Leadership Team
Inozyme Pharma today announced the addition of three industry veterans to its leadership team.

Trending Companies

Frequently Asked Questions